Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer.

Journal of cancer research and therapeutics - 1 Jan 2000

Isaakidou Athina, Gazouli Maria, Aravantinos Gerasimos, Pectasides Dimitrios, Theodoropoulos George E

Abstract excerpt

BACKGROUND: The aim of our study was to analyze the possible relationships between treatment efficacy, and germinal gene polymorphisms linked to the irinotecan in combination with bevasizumab or panitumumab and capecitabine or 5-FU that has been routinely used in our practice, in the management of metastatic colorectal cancer (CRC). MATERIALS AND METHODS: Ninety-four Greek with histologically proven metastatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Fluorouracil

Share to Greece

Share to Irinotecan

Share to Panitumumab

Source

Identifiers

PMID: 27072236
DOI: 10.4103/0973-1482.148654

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer.PMID 27072236Read ↗

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphismsSemantic proximity Read ↗

Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.Semantic proximity Read ↗

A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.Semantic proximity Read ↗

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms.Semantic proximity Read ↗

The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.Semantic proximity Read ↗

Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer.Semantic proximity Read ↗

UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.Semantic proximity Read ↗

Genotype-based chemotherapy for patients with gastrointestinal tumors: focus on oxaliplatin, irinotecan, and fluoropyrimidines.Semantic proximity Read ↗

Genotyping of DPYD and UGT1A1 in Brazilian oncological patients: applying pharmacogenomics in an admixed population.Semantic proximity Read ↗

Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced Colorectal Cancer Patients: An Exploratory Study.Semantic proximity Read ↗

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.Semantic proximity Read ↗

Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.